Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Westerhout, M. Treur, B. Bechtel (Rotterdam, Netherlands; Munich, Germany). Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany. Eur Respir J 2012; 40: Suppl. 56, 1296

Member's Comments

No comment yet.

Related content which might interest you: Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 The economic impact recurrent inhaler versus single instructions in asthma and COPD patients Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE) Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019